EGFR inhibitor - Eilean Therapeutics
Latest Information Update: 16 Oct 2024
At a glance
- Originator Eilean Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 04 Oct 2024 Preclinical trials in Cancer in USA (unspecified route) prior to October 2024 (Eilean Therapeutics pipeline; October 2024)